Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals.
Chalouni M, Rodriguez-Centeno J, Samri A, Blanco J, Stella-Ascariz N, Wallet C, Knobel H, Zucman D, Alejos Ferreras B, Autran B, Thiebaut R, Raffi F, Arribas JR; NEAT 001/ANRS 143 Trial Study Group. Chalouni M, et al. Among authors: arribas jr. PLoS One. 2020 Apr 8;15(4):e0230772. doi: 10.1371/journal.pone.0230772. eCollection 2020. PLoS One. 2020. PMID: 32267847 Free PMC article.
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA. Blasco AJ, et al. Among authors: arribas jr. Enferm Infecc Microbiol Clin. 2012 Jun;30(6):283-93. doi: 10.1016/j.eimc.2012.02.016. Epub 2012 Apr 22. Enferm Infecc Microbiol Clin. 2012. PMID: 22525829 Spanish.
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA. Blasco AJ, et al. Among authors: arribas jr. Enferm Infecc Microbiol Clin. 2013 Nov;31(9):568-78. doi: 10.1016/j.eimc.2013.06.002. Epub 2013 Aug 20. Enferm Infecc Microbiol Clin. 2013. PMID: 23969276 Spanish.
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Estébanez M, Stella-Ascariz N, Mingorance J, Pérez-Valero I, Bernardino JI, Zamora FX, Montes ML, González-García JJ, Arribas JR. Estébanez M, et al. Among authors: arribas jr. BMC Infect Dis. 2014 Jul 10;14:379. doi: 10.1186/1471-2334-14-379. BMC Infect Dis. 2014. PMID: 25015544 Free PMC article. Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Among authors: arribas jr. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Blasco AJ, Llibre JM, Berenguer J, González-García J, Knobel H, Lozano F, Podzamczer D, Pulido F, Rivero A, Tuset M, Lázaro P, Gatell JM; GESIDA ART Cost-efficacy Study Group. Blasco AJ, et al. Enferm Infecc Microbiol Clin. 2015 Mar;33(3):156-65. doi: 10.1016/j.eimc.2014.05.016. Epub 2014 Aug 28. Enferm Infecc Microbiol Clin. 2015. PMID: 25175171
No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
Solomon A, Tennakoon S, Leeansyah E, Arribas J, Hill A, Van Delft Y, Moecklinghoff C, Lewin SR. Solomon A, et al. PLoS One. 2014 Nov 4;9(11):e109718. doi: 10.1371/journal.pone.0109718. eCollection 2014. PLoS One. 2014. PMID: 25368992 Free PMC article. Clinical Trial.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Tuset M, Gatell JM; GeSIDA Antiretroviral Therapy Cost-efficacy Study Group. Berenguer J, et al. Among authors: arribas jr. Enferm Infecc Microbiol Clin. 2016 Jun-Jul;34(6):361-71. doi: 10.1016/j.eimc.2015.07.012. Epub 2015 Aug 28. Enferm Infecc Microbiol Clin. 2016. PMID: 26321131
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group. Bernardino JI, et al. Among authors: arribas jr. Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30. Lancet HIV. 2015. PMID: 26520926 Clinical Trial.
383 results